Consequences of switching from a fixed 2 : 1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli
Authors:
- J. Cohen StuartJSJ. Cohen Stuart
- on behalf of the ISIS-AR Study GroupOGon behalf of the ISIS-AR Study Group
- L. J. M. SabbeLSL. J. M. Sabbe
- H. M. E. FrenayHFH. M. E. Frenay
- B. MarahaBMB. Maraha
- P. H. J. van KeulenPKP. H. J. van Keulen
- J. A. J. W. KluytmansJKJ. A. J. W. Kluytmans
- B. M. de JonghBJB. M. de Jongh
- B. J. M. VlaminckxBVB. J. M. Vlaminckx
- E. I. G. B. de BrauwerEBE. I. G. B. de Brauwer
- F. S. StalsFSF. S. Stals
- L. J. BakkerLBL. J. Bakker
Open Access
- 13 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 68 (11) , 2636-2640
Abstract
The CLSI recommends a fixed 2 : 1 ratio of co-amoxiclav for broth microdilution susceptibility testing of Enterobacteriaceae, while EUCAST recommends a fixed 2 mg/L clavulanate concentration. The aims of this study were: (i) to determine the influence of a switch from CLSI to EUCAST methodology on Escherichia coli susceptibility rates; (ii) to compare susceptibility results obtained using EUCAST-compliant microdilution with those from disc diffusion and the Etest; and (iii) to evaluate the clinical outcome of patients with E. coli sepsis treated with co-amoxiclav in relation to the susceptibility results obtained using either method. Resistance rates were determined in three laboratories that switched from CLSI to EUCAST cards with the Phoenix system (Becton Dickinson) as well as in 17 laboratories that continued to use CLSI cards with the VITEK 2 system (bioMérieux). In one laboratory, isolates were simultaneously tested by both the Phoenix system and either disc diffusion (n = 471) or the Etest (n = 113). Medical and laboratory records were reviewed for E. coli sepsis patients treated with co-amoxiclav monotherapy. Only laboratories that switched methodology showed an increase in resistance rates – from 19% in 2010 to 31% in 2011 (P < 0.0001). All isolates that tested susceptible by microdilution were also susceptible by disc diffusion or the Etest, but of 326 isolates that tested resistant by microdilution, 43% and 59% tested susceptible by disc diffusion and the Etest, respectively. Among the 89 patients included there was a better correlation between clinical response and measured MICs using the Phoenix system than the Etest. EUCAST methodology resulted in higher co-amoxiclav E. coli resistance rates than CLSI methodology, but correlated better with clinical outcome. EUCAST-compliant microdilution and disc diffusion provided discrepant results.Keywords
This publication has 7 references indexed in Scilit:
- Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemiaClinical Microbiology and Infection, 2012
- Assessment of the Phoenix™ automated system and EUCAST breakpoints for antimicrobial susceptibility testing against isolates expressing clinically relevant resistance mechanismsClinical Microbiology and Infection, 2012
- Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilliJournal of Antimicrobial Chemotherapy, 2011
- Increasing Antimicrobial Resistance and the Management of Uncomplicated Community-Acquired Urinary Tract InfectionsAnnals of Internal Medicine, 2001
- Fixed or variable concentrations of βlactamase inhibitors in in-vitro tests?Journal of Antimicrobial Chemotherapy, 1996
- Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combinationEuropean Journal of Clinical Microbiology & Infectious Diseases, 1982
- Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patientsAntimicrobial Agents and Chemotherapy, 1982